Cyclopharm Ltd
ASX:CYC
Intrinsic Value
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. [ Read More ]
The intrinsic value of one CYC stock under the Base Case scenario is 3.857 AUD. Compared to the current market price of 1.795 AUD, Cyclopharm Ltd is Undervalued by 53%.
Valuation Backtest
Cyclopharm Ltd
Run backtest to discover the historical profit from buying and selling CYC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cyclopharm Ltd
Current Assets | 30.2m |
Cash & Short-Term Investments | 11.7m |
Receivables | 7.9m |
Other Current Assets | 10.6m |
Non-Current Assets | 15.7m |
PP&E | 9.2m |
Intangibles | 5.7m |
Other Non-Current Assets | 796.1k |
Current Liabilities | 8.7m |
Accounts Payable | 6.9m |
Other Current Liabilities | 1.7m |
Non-Current Liabilities | 5m |
Long-Term Debt | 4m |
Other Non-Current Liabilities | 973k |
Earnings Waterfall
Cyclopharm Ltd
Revenue
|
27.8m
AUD
|
Cost of Revenue
|
-10.3m
AUD
|
Gross Profit
|
17.5m
AUD
|
Operating Expenses
|
-26.1m
AUD
|
Operating Income
|
-8.6m
AUD
|
Other Expenses
|
3.9m
AUD
|
Net Income
|
-4.7m
AUD
|
Free Cash Flow Analysis
Cyclopharm Ltd
What is Free Cash Flow?
CYC Profitability Score
Profitability Due Diligence
Cyclopharm Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Cyclopharm Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
CYC Solvency Score
Solvency Due Diligence
Cyclopharm Ltd's solvency score is 94/100. The higher the solvency score, the more solvent the company is.
Score
Cyclopharm Ltd's solvency score is 94/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYC Price Targets Summary
Cyclopharm Ltd
According to Wall Street analysts, the average 1-year price target for CYC is 3.876 AUD with a low forecast of 3.838 AUD and a high forecast of 3.99 AUD.
Shareholder Return
CYC Price
Cyclopharm Ltd
Average Annual Return | 15.9% |
Standard Deviation of Annual Returns | 69.48% |
Max Drawdown | -71% |
Market Capitalization | 168.9m AUD |
Shares Outstanding | 94 096 300 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.
Contact
IPO
Employees
Officers
The intrinsic value of one CYC stock under the Base Case scenario is 3.857 AUD.
Compared to the current market price of 1.795 AUD, Cyclopharm Ltd is Undervalued by 53%.